about
Dopamine and Somatostatin Analogues Resistance of Pituitary Tumors: Focus on Cytoskeleton InvolvementInterpreting biochemical control response rates with first-generation somatostatin analogues in acromegalyThe effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegalyThe Treatment of Cushing's Disease.Place of preoperative treatment of acromegaly with somatostatin analog on surgical outcome: a systematic review and meta-analysisThe Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptorsClinical Importance of Somatostatin Receptor 2 (SSTR2) and Somatostatin Receptor 5 (SSTR5) Expression in Thyrotropin-Producing Pituitary Adenoma (TSHoma).Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guidelineClinical applications of somatostatin analogs for growth hormone-secreting pituitary adenomasA structural and functional acromegaly classificationIdentification of somatostatin receptor type 5 gene polymorphisms associated with acromegalyTruncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomasPasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study.Homologous and heterologous in vitro regulation of pituitary receptors for somatostatin, growth hormone (GH)-releasing hormone, and ghrelin in a nonhuman primate (Papio anubis).Reflections on the theory of "silver bullet" octreotide tracers: implications for ligand-receptor interactions in the age of peptides, heterodimers, receptor mosaics, truncated receptors, and multifractal analysis.Medical management of functioning pituitary adenoma: an update.Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study.Molecular Characterization of Growth Hormone-producing Tumors in the GC Rat Model of AcromegalyDifferential somatostatin receptor (SSTR) 1-5 expression and downstream effectors in histologic subtypes of growth hormone pituitary tumorsLong-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes.A consensus on the diagnosis and treatment of acromegaly complications.Illuminating somatostatin analog action at neuroendocrine tumor receptorsThe role of primary pharmacological therapy in acromegaly.Loss of Efficacy of Pasireotide After its Re-Administration: is There a Reason Why?BIM-23A760 influences key functional endpoints in pituitary adenomas and normal pituitaries: molecular mechanisms underlying the differential response in adenomas.FGFR4 polymorphic alleles modulate mitochondrial respiration: A novel target for somatostatin analog action in pituitary tumorsExpression of Somatostatin Receptor 2 in Somatotropinoma Correlated with the Short-Term Efficacy of Somatostatin AnaloguesOctreotide long-acting repeatable for acromegaly.Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience.The place of medical treatment of acromegaly: current status and perspectives.Investigational therapies for acromegaly.Aggressive tumors and difficult choices in acromegaly.Gastrointestinal neuroendocrine tumors (NETs): new diagnostic and therapeutic challenges.Emerging drugs for acromegaly.Pharmacological treatment of acromegaly: its place in the overall therapeutic approach.Aggressive pituitary adenomas--diagnosis and emerging treatments.Treatment of acromegaly in the era of personalized and predictive medicine.Adverse events associated with somatostatin analogs in acromegaly.Management of aggressive growth hormone secreting pituitary adenomas.Expression of somatostatin receptor subtype 2 in growth hormone-secreting pituitary adenoma and the regulation of miR-185.
P2860
Q26770701-C4E130EC-410B-4301-A601-349C317C2518Q26777682-97BC721D-0DB6-4B38-BB79-AB17A49DCFBFQ26796357-6A33C1D7-8F54-4C3E-9BAF-53F0D9045F28Q27010590-563E514A-4A1F-4FB6-9921-57DD53973BD2Q27693237-6CB7AE4E-8AC9-4F8D-8F88-64B05F6D6517Q30486707-FE9F2119-D029-44C4-9CC6-8C2780E6B505Q33620709-462E3EBC-B974-46FF-BE2A-24829AE2844AQ34277844-0099A0C5-EDBE-43DE-AB64-7D7A3C6EF2E1Q34658946-F8B75DAB-8FAF-4083-A016-FD40AA8ADE26Q34810811-A5DC31A9-E085-4156-9461-146852F2A002Q35228807-F15724EF-8D8D-4526-A45A-694E6AFE44FFQ35228970-C8FF864E-5F52-4AE3-982A-450423762905Q35582894-D9C24834-F1A7-483E-AD97-B5755532BB55Q35646087-0CAC7130-8C84-4355-81B3-E3C372803F4AQ35650633-E8003717-F4B3-496C-87FE-4E8B9B1BC4D9Q35943493-49B9E183-1465-46E8-B1F4-14ABA69FF950Q35977997-D1868ECA-6CE7-4B3B-9EF6-DFD240AE7772Q36262428-0377C75E-745B-4C35-B58D-64CFC37D9362Q36270932-81D67E08-2093-4619-8A6C-2F6BFDD535A2Q36964536-BF9C6DAF-0202-4063-B6A4-013D77C1950DQ37061155-32069E68-1C7C-46F6-A6D7-D4BB7EEC77E4Q37443562-471B3031-5D59-4BB6-901D-01A93C52321CQ37531005-33CEEE04-D860-4C0E-9AFD-32A5FC122F0DQ37579710-296CC0E8-8F3B-406C-AA0A-C8C89CB77B97Q37633385-3206E78C-A341-42FA-A673-6BE1D322C96BQ37709494-B26D4A47-A8BF-43B6-97D7-3AD4F127B38CQ37726440-88A67A55-1C5D-4E48-8848-9A402DA30E62Q37990556-0DEF6622-6DB6-4C1D-9A46-670B1FE70730Q38062852-A886D87D-8EDC-4B2E-BF2E-8B80079FBE3FQ38100275-BCCFE2C7-413D-452B-A436-D610F562E2B5Q38111437-A477B53F-3A9A-4E34-A941-51B20B9D5E60Q38167711-76F30726-9261-4290-90DE-75811DA85F14Q38175857-8E30281C-5545-4DD5-BBC9-D04B010DB1D9Q38176659-EA876617-B139-491F-8167-6F64C93386E4Q38179982-0733C74A-8B6A-4852-9879-8FA603FB9DC7Q38211375-805B4CDB-7301-4388-882C-F6940294E151Q38340014-B83490B0-36EE-4103-BB7E-6EDBCB12C785Q38548973-0541F2C3-42E2-411C-8D31-4813520325D6Q38781620-FCDFB824-8937-4349-BB3C-A6BFF705115EQ38868233-EAFF21F7-1D45-4908-8A52-BB1C54371ACD
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Resistance to somatostatin analogs in acromegaly.
@en
Resistance to somatostatin analogs in acromegaly.
@nl
type
label
Resistance to somatostatin analogs in acromegaly.
@en
Resistance to somatostatin analogs in acromegaly.
@nl
prefLabel
Resistance to somatostatin analogs in acromegaly.
@en
Resistance to somatostatin analogs in acromegaly.
@nl
P50
P356
P1433
P1476
Resistance to somatostatin analogs in acromegaly.
@en
P2093
Renata S Auriemma
P304
P356
10.1210/ER.2010-0002
P577
2010-12-01T00:00:00Z